Corange expects 14% growth in turnover for 1995:
This article was originally published in Clinica
Corange, parent of Boehringer Mannheim and DePuy, expects to record turnover of $3,950 million in 1995, an increase of 14% on the previous year, reports Handelsblatt. Growth of the diagnostics business is particularly strong and the company expects this trend to continue throughout 1996.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.